US › Healthcare

Ocugen Inc (OCGN)

US · Healthcare · Biotechnology

$1.03+3.21%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.5M

Revenue YoY

+8.4%

Net profit

$-24.9M

EPS

$-0.07

EPS estimate

$-0.05

Net margin

-1,671.8%

EPS came in at -0.07 against a street estimate of -0.05 — a miss of 40.0%.

Key statistics

Market cap

$345.9M

Forward P/E

13.1

P/B

75.94

Book value

$-0.05

EPS (TTM)

$-0.26

52-week high

$2.73

52-week low

$1.01

50-day MA

$1.33

200-day MA

$1.51

Beta

2.21

Analyst view

Analysts rate Ocugen Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $12.08.

Shareholding

Insiders

1.68%

Institutions

43.29%

Largest institutional holders

Fund	Stake
Millennium Management LLC	4.11%
Vanguard Capital Management, LLC	4.07%
State Street Corp	2.85%
Marshall Wace Asset Management Ltd	2.37%
BlackRock Inc	2.15%
UBS Group AG	2.15%
RTW INVESTMENTS, LLC	1.97%
Geode Capital Management, LLC	1.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ocugen Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.